Wedbush analyst Liana Moussatos reiterated a Buy rating on Verona Pharma Plc (VRNA) today and set a price target of $58. The company’s shares opened today at $5.92, close to its 52-week low of $5.52.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.6% and a 36.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
Currently, the analyst consensus on Verona Pharma Plc is a Moderate Buy with an average price target of $27.67.
See today’s analyst top recommended stocks >>
Based on Verona Pharma Plc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.04 million. In comparison, last year the company had a GAAP net loss of $21.18 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. It’s product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
